Aristopharma Ltd

Our Products

Filgen (Filgrastim)

Therapeutic Group : Granulocyte Colony Stimulating Factor

Share on facebook
Share on twitter
Share on print
Share on email
Mechanism of action: Filgrastim is a 175 amino acid human granulocyte colony-stimulating factor (G-CSF) manufactured by recombinant DNA technology. Filgrastim regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation and differentiation. It also causes the enhanced phagocytic ability‚ priming of the cellular metabolism associated with respiratory burst‚ antibody-dependent killing and the increased expression of some cell surface antigens. Pharmacokinetics: Filgrastim exhibits nonlinear pharmacokinetics. Clearance is dependent on Filgrastim concentration and neutrophil count. Filgrastim is cleared by kidney. It has a tmax of 2 to 8 hours. The absolute bioavailability of Filgrastim after subcutaneous administration is 60 - 70%.